• Policy
• Sotyktu, Livtencity to be reimb from April
• by Lee, Jeong-Hwan Mar 25, 2024 05:59am

• InterView
• ‘New head, new drugs…Bayer’s transition has just begun'
• by Eo, Yun-Ho Mar 25, 2024 05:59am

• Policy
• Expanded ‘pre-notification for change approval’
• by Lee, Hye-Kyung Mar 25, 2024 05:59am

• Policy
• Samsung Bioepis’s Soliris biosimilar is introduced
• by Lee, Tak-Sun Mar 25, 2024 05:59am

• Company
• K-bio, R&D global competitiveness will be put to the test
• by Son, Hyung-Min Mar 22, 2024 06:09am

• Company
• Lotte Biologics’ sales amount to KRW 228.6 billion
• by Kim, Jin-Gu Mar 22, 2024 06:09am

• Policy
• Economic benefits paid to doctors to be publicly disclosed
• by Lee, Jeong-Hwan Mar 22, 2024 06:08am

• Company
• Antihistamine sales benefit from end of pandemic and endemic
• by Son, Hyung-Min Mar 22, 2024 06:06am

• Company
• Luxturna prescriptions available for rare retinal disease
• by Eo, Yun-Ho Mar 22, 2024 06:06am

• Policy
• Enhertu’s price falls to KRW 70 mil range with reimb
• by Lee, Tak-Sun Mar 22, 2024 06:06am